This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment

Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment

Format

Webcast

Time to Complete

1 hour

Released

December 15, 2017

Expires

December 15, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE for Nurses (0.70 pharmacotherapy hours)
1.00 / CE for Pharmacists (0.10 CEUs)
1.00 / CPEU for Registered Dietitians

Accredited Provider

This activity is jointly provided by Global Education Group and the Cardiometabolic Health Congress.

Commercial Supporter

This activity is supported by an educational grant from Sanofi US.

Program Description

The prevalence of T2DM in the United States is 29.1 million and it is the seventh leading cause of death and a major cause of morbidity, including microvascular, macrovascular, cerebrovascular, and peripheral vascular disease complications. Clinicians face several challenges in helping patients with T2DM reach their glycemic goals, including an increasing armamentarium which gives rise to confusion regarding proper selection and sequence, multiple sets of available evidence-based guidelines, and “clinical inertia” – the failure to close the gap between best practice and the patient’s usual level of care. The goal of this symposium is to increase awareness among clinicians of the challenges in reaching T2DM glycemic targets, to review the clinical guidelines for T2DM treatment using an array of antihyperglycemic agents, and to present evidence on emerging basal insulin/GLP-1RA fixed-ratio combination products.

Intended Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including: physicians (MDs), nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists (ACPE), dieticians (CDR), and other allied health professionals.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Outline the stepwise approach to T2DM treatment as recommended by current ADA/EASD and AACE/ACE guidelines
  • List potential barriers to treatment escalation in T2DM and the role of clinical inertia in reaching glycemic targets
  • Describe the complementary actions of basal insulin and GLP-1RA inhibitors in treating T2DM
  • Identify the role of emerging fixed-ratio basal insulin/GLP-1RA products in the treatment of patients with T2DM

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Chair:
Robert H. Eckel, MD

Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics
Charles A. Boettcher II Chair in Atherosclerosis
Director, T32 in Obesity and Cardiovascular Disease
University of Colorado Anschutz Medical Campus
Director, Lipid Clinic, University Hospital
Aurora, CO

Dr. Eckel discloses the following:
Consultant/Independent Contractor: Sanofi/Regeneron-Expert Witness

Yehuda Handelsman, MD
Medical Director and Principal Investigator
Metabolic Institute of America
Tarzana, CA

Dr. Handelsman discloses the following:
Grant/Research Support: Amgen, AstraZeneca, BMS, BI, Grifols, Janssen, Lexicon, Merck, Novo Nordisk, Sanofi.
Advisory/Consultant: Amarin, Amgen, AstraZeneca, BI, Eisai, Intarcia, Lilly, Janssen, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, Sanofi.
Speakers Bureau: Amarin, Amgen, AstraZeneca, BI-Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Regeneron.

Dr. Handelsman and his immediate family do not have ownership interest and/or stocks of any Pharmaceutical or device company.

Athena Philis-Tsimikas, MD
Corporate Vice President
Scripps Whittier Diabetes Institute
San Diego, CA

Dr. Philis-Tsimikas discloses the following:
Consultant/Independent Contractor: Advisory board on behalf of Scripps Health for Astra Zeneca, DexCom, Lilly, Novo Nordisk, Sanofi (no direct or indirect reimbursement to advisor)
Grant/Research Support: Janssen, Lilly, Novo Nordisk, Sanofi, (No direct or indirect reimbursement to researcher)
Stock Shareholder: Ionis, Gilead, Novo Nordisk, Esperion

Julio Rosenstock, MD
Director, Dallas Diabetes and Endocrine Center
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Dr. Rosenstock discloses the following:
Consultant/Independent Contractor: I have served on scientific advisory boards and received honorarium or consulting fees from the following: Roche, Sanofi, Novo Nordisk, Eli Lilly, Daiichi Sankyo, AstraZeneca, Janssen, Boehringer-Ingelheim, Lexicon, and Intarcia
Grant/Research Support: Merck, Pfizer, Sanofi, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Takeda, AstraZeneca, Janssen, Daiichi Sankyo, Lexicon, Boehringer-Ingelheim, and Intarcia

Accredited Provider Disclosure

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN, has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Erin Franceschini, MS, has nothing to disclose.
Karin McAdams has nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this virtual activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This educational activity for 1.00 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This activity includes 0.70 pharmacotherapy hour.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

Global Education Group designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity.

Universal Activity Number (UAN): 0530-9999-17-448-H01-P

Credit

1.00

Type

CPEU Credit

Accreditation Statement

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statement

CDR Credentialed Practitioners will receive 1.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials.

CPE Provider #GE012

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue